Hypercoagulable state and methylenetetra- hydrofolate reductase (MTHFR) C677T mutation in patients with beta-thalassemia major in kuwait

Acta Haematologica

Volumn 123, Issue 1, 2009, Pages 37-42

  Mustafa, Nada Y ^a   Marouf, Rajaa ^a   Al Humood, Salah ^a   Al Fadhli, Suad M ^a   Mojiminiyi, Olusegun ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

Thalassemia major; Hypercoagulable state; Kuwait; Methylenetetrahydrofolate reductase (MTHFR) C677T mutation

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTITHROMBIN; HOMOCYSTEINE; LUPUS ANTICOAGULANT; PROTEIN C; PROTEIN S; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); PRIMER DNA;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; BETA THALASSEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; FEMALE; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; KUWAIT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ADOLESCENT; BLOOD; BLOOD CLOTTING DISORDER; CASE CONTROL STUDY; GENETICS; HOMOZYGOTE; METABOLISM; NUCLEOTIDE SEQUENCE; POINT MUTATION; THROMBOEMBOLISM;

ACTIVATED PROTEIN C RESISTANCE; ADOLESCENT; ADULT; ANTITHROMBINS; BASE SEQUENCE; BETA-THALASSEMIA; BLOOD COAGULATION DISORDERS; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; HETEROZYGOTE; HOMOCYSTEINE; HOMOZYGOTE; HUMANS; KUWAIT; LUPUS COAGULATION INHIBITOR; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POINT MUTATION; PROTEIN C; PROTEIN S; RISK FACTORS; THROMBOEMBOLISM; YOUNG ADULT;

EID: 70450193544     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000260069     Document Type: Article

References (21)

1. Harrison CR: Hemolytic anemias: intracorpuscular defect. IV. Thalassemia; in Harmening DM (ed): Clinical Hematology and Fundamentals of Hemostasis, ed 4. Philadelphia, Davis, 2002, pp 186-199.
2. Olivieri NF: The -thalassemias. N Engl J Med 1999; 341: 99-109.
3. Adekile AD, Gu LH, Baysal E, Haider MZ, Al-Fuzae L, Aboolbacker KC, al-Rashied A, Huisman THJ: Molecular characterization of-thalassemia determinants,-thalassemia alleles, and -S haplotypes among Kuwaiti Arabs. Acta Haematol 1994; 92: 176-181.
4. Al-Fuzae L, Aboolbacker CK, Al-Saleh Q:Thalassemia major in Kuwait. J Trop Pediatr 1998; 44: 311-312.
5. Cunningham MJ, Macklin EA, Nenfeld EJ, Cohen AR: Complications of-thalassemia major in North America. Blood 2004; 104: 34-39.
6. Hoffbrand AV, Pettit JE, Moss PAH: Genetic disorders of haemoglobin; in Essential Haematology, ed 4. Oxford, Blackwell, 2002, pp 71-90.
7. Barrano B, Bertrand G, Lsaja T, Curreri R, Musumeci S: Plasma homocysteine is not involved in the thrombotic risk of-thalassemia major patients. Acta Haematol 2000; 104: 148-150.
8. Eldor A, Rachmilewitz EA: The hypercoagulable state in thalassemia. Blood 2002; 99: 36-43.
9. Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA: Thromboembolic complications in beta thalassemia major. Acta Haematol 1992; 87: 71-74.
10. Moratelli S, De Sanctis V, Gemmati D, Serino ML, Mari R, Gamberini MR, Scapoli GL: Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab 1998; 11: 915-921.
11. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, Forni GL, Gamberini MR, Ghilardi R, Piga A, Cnaan A: Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193.
12. Eldor A, Durst R, Hy-Am E, Goldfarb A, Gillis S, Rachmilewitz EA, Abramov A, Maclouf J, Godefray YC, De Raucourt E, Guillin MC: A chronic hypercoagulable state in patients with-thalassemia major is already present in childhood. Br J Haematol 1999; 107: 739-746.
13. Giordano P, Sabato V, Schettini F, De Mattia D, Iolascon A: Resistance to activated protein C as a risk factor of stroke in a thalassemic patient. Haematologica 1997; 82: 698-700.
14. Giordano P, Del Vecchio GC, Altomare M, Coppola B, Schettini F, Lolascon A, De Maffia D: Resistance to activated protein C in thalassemic patients: an underlying cause of thrombosis. Eur J Haematol 1998; 61: 123-127.
15. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008.
16. Kassab-Chekir A, Laradi S, Ferchichi S, Khelil AH, Feki M, Amri F, Selmi H, Bejaoui M, Miled A: Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 2003; 338: 79-86.
17. Mojtahedzadeh F, Kosaryan M, Mahdavi MR, Akbari J: The effect of folic acid supplementation in beta thalassemia major: a randomized placebo controlled clinical trial. Arch Iran Med 2006; 9: 266-268.
18. Kosaryan M, Mahdavi MR, Shahmoradi M, Arabzadeh M: Is it necessary to give folic acid to thalassemia minor or major? International Congress on Pediatrics, Tehran, 2003.
19. Rahimi Z, Ghaderi M, Nagel RL, Muniz A: Prevalence of thrombotic risk factors among-thalassemia patients from Western Iran. J Thromb Thrombolysis 2008; 26: 229-233.
20. Chaloupecky V, Svobodova I, Hadacova I, Tomek V, Huín B, Tláskal T, Janoušek J, Reich O, Škovránek J: Coagulation profile and liver function in 102 patients after total cavopulmonary connection at mid term follow up. Heart 2005; 91: 73-79.
21. Sipahi T, Kara A, Kuybulu A, Egin Y, Akar N: Congenital thrombotic risk factors in betathalassemia. Clin Appl Thromb Hemost 2008, E-pub ahead of print. doi:10.1177/1076 029608316170.